Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine

Last updated: December 6, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting

Phase

4

Condition

Anesthesia

Treatment

RSI succinylcholine

Modified Time Principle Induction (MTPI) with rocuronium

Clinical Study ID

NCT06029049
HSC-MS-23-0468
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess and compare conditions for tracheal intubation obtained with modified time principal induction with 0.6 mg/kg rocuronium and 1 mg/kg succinylcholine. Specifically, the investigators will be evaluating ease of laryngoscopy, vocal cord view, vocal cord opening, and movement of limbs and coughing during tracheal intubation in order to assess intubation conditions, to compare efficiency and success rate of tracheal intubation between two induction agents and to determine the rate of patient awareness during induction and post-operative recall of paralysis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • BMI > 30kg/m2 or Mallampati class III or IV.

  • Requiring general anesthesia and endotracheal intubation

Exclusion

Exclusion Criteria:

  • Acute and chronic respiratory disorders, including Chronic obstructive pulmonarydisease(COPD) and asthma.

  • The American Society of Anesthesiologists (ASA) physical status classification >III.

  • Patients requiring awake intubation.

  • Pregnant women.

  • Untreated ischemic heart disease.

  • Patients requiring an induction dose of propofol < 1 mg/kg.

  • Allergy to propofol, rocuronium, succinylcholine, or sugammadex.

  • Patients with renal failure and unknown potassium (K+) level, or patients with K+level > 5.0

  • Personal history of malignant hyperthermia (MH), or family history of MH

  • Patients with suspected or diagnosed neuromuscular disease, patients with burninjuries

Study Design

Total Participants: 152
Treatment Group(s): 2
Primary Treatment: RSI succinylcholine
Phase: 4
Study Start date:
September 13, 2023
Estimated Completion Date:
July 01, 2025

Connect with a study center

  • The University of Texas Health Science Center at Houston

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.